Business
BioMarin develops and markets therapies for genetically defined rare diseases.
BioMarin delivered double-digit growth, higher profit and strong free cash flow, while a $240 million restructuring and pending Amicus acquisition materially changed the forward setup.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 12.9%OK
- Profitability — Net income declined 18.3% to $348.901M from $426.859MWatch
- Cash flow — Free cash flow grew 48.7% to $724.956M from $487.417MOK
- Margins — Operating margin contracted 426 bps to 12.71%Watch
- Accounting — Rare-disease growth with restructuring and deal riskNote
- Insiders — 0 purchases and 4 salesNote
Where the revenue comes from
Fiscal 2025, as BIOMARIN PHARMACEUTICAL INC reports it. History and quarterly detail are in the app.
- Product$3.2B
- Products excluding ALDURAZYME$3.0B
- Royalty and other revenues$53.5M
Leadership changes
From BIOMARIN PHARMACEUTICAL INC's own filings, the day they're filed.
- Rashmi Ramchandani · President · appointmenteff. 2026-01-19
- Ian T. Clark · director · appointmenteff. 2025-08-01
- Henry J. Fuchs · President · departureeff. 2025-03-03
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-31
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIOMARIN PHARMACEUTICAL INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.